06:55 AM EDT, 08/19/2024 (MT Newswires) -- Daiichi Sankyo said Monday that a Type II Variation application for its breast cancer therapy Enhertu, jointly developed with AstraZeneca ( AZN ) , is now up for review with the European Medicines Agency.

The application adds an indication of Enhertu as treatment for an advanced breast cancer that can't be surgically removed or has spread to other parts of the body, Daiichi Sankyo said.

Price: 84.52, Change: +0.11, Percent Change: +0.13